局部进展期直肠癌放化疗期间游离肿瘤DNA动态与早期MRI反应相关
在16例局部进展期直肠癌患者长程新辅助放化疗期间每周采血检测游离肿瘤DNA(ctDNA),共86份样本,分析其动态与初始肿瘤体积、放疗第2周和第5周MRI反应及术后病理反应和结局参数的相关性。多数患者ctDNA下降,但动态异质,可分为下降、无明显下降和/或晚期释放、持续存在三组;本探索性队列中ctDNA动态与病理反应或结局参数无显著相关,但ctDNA明显下降者治疗前肿瘤体积更大、第2周和第5周MRI肿瘤体积绝对缩小更多。
要点
- 长程新辅助放化疗期间每周检测ctDNA可行,可能是有前景的生物标志物。
- ctDNA动态异质,可分为下降、无明显下降和/或晚期释放、持续存在三组。
- 本探索性队列中ctDNA动态与病理反应或结局参数无显著相关。
核心结论
- 放化疗期间每周检测ctDNA可行,可能是有前景的生物标志物。
- 较大的初始原发肿瘤与较小原发肿瘤相比表现出不同的ctDNA释放特征。
- 发现了ctDNA动态与早期影像学反应之间的相关性。
研究设计与样本
- 在16例局部进展期直肠癌患者长程新辅助放化疗期间每周采血检测ctDNA,共分析86份血样。
- 将ctDNA数据与初始肿瘤体积、放疗第2周和第5周MRI反应以及切除术后病理肿瘤反应和结局参数进行相关性分析。
主要发现
- 多数患者在放化疗过程中ctDNA下降,但动态异质,可识别出下降、无明显下降和/或晚期释放、持续存在三组。
- 在7例患者治疗第5周或第6周可检测到显著数量的ctDNA。
- 本探索性队列中未发现ctDNA动态与病理反应或结局参数之间存在显著相关性。
- ctDNA明显下降的患者治疗前肿瘤体积更大,且第2周和第5周MRI显示肿瘤体积绝对缩小更大。
- 若第5周和/或第6周发现显著水平ctDNA,患者第2周和第5周肿瘤体积绝对缩小较少。
局限性
- 本探索性队列中未发现ctDNA动态与病理反应或结局参数之间存在显著相关性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In locally advanced rectal cancer, the prediction of tumor response during and after neoadjuvant treatment remains challenging. In terms of organ preservation, adaptive radiotherapy, and intensified (total) neoadjuvant therapies, biomarkers are desirable for patient stratification. METHODS: In 16 patients, weekly blood samples (n = 86) to detect cell-free tumor DNA (ctDNA) during long-course neoadjuvant chemoradiotherapy were analyzed. Data were correlated with initial tumor volumes, MRI response in week 2 and 5 of radiotherapy as well as with pathologic tumor response after resection and outcome parameters. RESULTS: Most patients showed decreasing ctDNA during the course of radiochemotherapy. However, we found heterogenous dynamics of ctDNA and could identify three groups: (1) decline (2) no clear decline and/or late shedding (3) persistence of ctDNA. In seven patients we could detect significant amounts of ctDNA in week 5 or week 6 of treatment. In our pilot cohort, we did not find significant correlations of ctDNA dynamics with pathologic response or outcome parameters. However, patients with distinct decline of ctDNA had larger tumor volumes prior to treatment, and MRI imaging in week 2 and 5 revealed bigger absolute decrease of tumor volumes. If significant levels of ctDNA were found in week 5 and / or 6, patients showed less absolute tumor volume decrease in week 2 and 5. CONCLUSIONS: Weekly measurement of ctDNA during radiochemotherapy is feasible and might represent a promising biomarker. Bigger initial primary tumors showed different ctDNA shedding profiles compared with smaller primary tumors and correlations of ctDNA dynamics with early imaging response were found.
引用
- Clasen K, Gani C, Schuetz L, et al. Dynamics of cell-free tumor DNA correlate with early MRI response during chemoradiotherapy in rectal cancer. Radiat Oncol. 2024. PMID: 39506775. doi:10.1186/s13014-024-02540-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。